Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
  • C07D303/02—Compounds containing oxirane rings
  • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
  • C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
  • C07C271/06—Esters of carbamic acids
  • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
  • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2603/00—Systems containing at least three condensed rings
  • C07C2603/56—Ring systems containing bridged rings
  • C07C2603/86—Ring systems containing bridged rings containing four rings

Definitions

• the invention relates to new pharmacologically active compounds, which have the power to influence tubulin polymerization or tubulin depolymerization.
• mitotic poisons are used as anti-tumor agents or are undergoing clinical trials.
• a spindle device e.g., vinca alkaloids, colchicine
• mitotic poisons Owing to previously little-understood physicochemical properties and the characteristics of neoplastic cells, mitotic poisons have a certain selectivity for tumor cells, but there is also significant cytotoxicity with regard to nontransformed cells.
• Taxanes have very recently opened up important applications that were not accessible by previously available cytostatic agents, e.g., ovarian cancers, malignant melanomas.
• cytostatic agents e.g., ovarian cancers, malignant melanomas.
• the side effects of taxanes are comparable to those of other cytostatic agents, however (e.g., loss of hair, sensory neuropathy).
• Multi-drug-resistant tumor cells which over-express the P-glycoprotein, are resistant to taxanes.
• the limited availability of the natural substance taxol also inhibits broader clinical trials.
• Tubulin is an essential component of the mitotic spindle. It is used, i.a., to preserve the cell shape, to transport organelles inside the cell, and to influence cell mobility.
• taxanes have represented the only known structural class that is able to accelerate the polymerization of tubulin (mainly in the G2 phase), as well as to stabilize the microtubuli polymers formed. This mechanism is clearly distinguishable from those that have other structural classes which also influence the phase-specific cell division.
• substances from the group of vinca alkaloids e.g., vincristines and vinblastines
• colchicine inhibit the polymerization of the tubulin dimers in the M phase.
• R 1 means C(O)--CH(OR 6 )--CH(NHR 7a R 7b )--R 8 , C(O)--CH(OR 6a )--CH[NH(C(O)--CH(OR 6b )--CH(NR 7a R 7b )--R 8 )]--R 8 ,
• R 2 means hydrogen, --OH, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, --OC(O)R 9a , --OSO 2 R 9a , --OP(O)(OH) 2 , NHR 9a , NR 9a R 9b ,
• R 3 means hydrogen, --OH, C 1 -C 10 alkoxy, --OC(O)R 9b , --OSO 2 R 9b , --OP(O)(OH) 2 , or
• R 2 , R 3 together mean an oxygen atom
• R 4 means hydrogen, C 1 -C 10 alkyl, --(CH 2 ) n --OR 11a ,
• R 5 means hydrogen, C 1 -C 10 alkyl, --(CH 2 ) p --OR 11b , or
• R 4 , R 5 together mean an oxygen atom, a ⁇ CHR 10 group,
• R 6a , R 6b are the same or different and mean R 6 ,
• R 7a , R 7b are the same or different and mean R 7 ,
• n 0 to 8
• R 7 means --C(O)R 12 1 , --SO 2 R 12 , --C(O)OR 12 , --C(O)SR 12 , --C(O)NHR 9d , --C(O)NR 9d R 9e , C 1 -C 10 alkyl, ##STR3##
• R 8 means phenyl, R 9a-e , R 12 are the same or different and mean C 1 -C 10 alkyl, C 4 -C 8 cycloalkyl, aryl, C 7 -C 16 aralkyl,
• R 10 means hydrogen, C 1 -C 10 alkyl, --(CH 2 ) s --OR 14 ,
• s means 1 to 8
• R 6 , R 11a ,b, R 14 are the same or different and mean hydrogen, C 1 -C 10 alkyl, aryl, C 1 -C 10 acyl, C 7 -C 16 aralkyl, --SO 2 R 9c , --P(O)(OH) 2 ,
• R 13 , R 15a ,b are the same or different and mean hydrogen, C 1-C 10 alkyl, aryl, C 7 -C 16 aralkyl,
• X 1 , X 2 are the same or different and mean X
• X can be hydrogen, halogen, --OH, --NO 2 , --N 3 , --CN, --NR 15a R 15b , --NHSO 2 R 15a , --CO 2 R 15 , C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 acyloxy, C 1 -C 10 acyl,
• R 15 means hydrogen, their salts with physiologically compatible bases, as well as their ⁇ -, ⁇ - or ⁇ -cyclodextrin clathrates, as well as the compounds of general formula I that are encapsulated with liposomes.
• the invention relates to the diastereomers and/or enantiomers of these borneol derivatives and also their mixtures.
• alkyl groups R 2 , R 4 , R 5 , R 6 , R 9a-e , R 10 R 11a ,b, R 12 , R 13 , R 14 , R 15a ,b and X straight-chain or branched-chain alkyl groups with 1-10 carbon atoms can be considered, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, heptyl, hexyl, decyl.
• Alkyl groups R 2 , R 4 , R 5 , R 6 , R 9a-e , R 10 , R 11a ,b, R 12 , R 13 , R 14 , R 15a ,b, and X can be substituted by 1-3 halogen atoms, hydroxy groups, C 1 -C 4 alkoxy groups, C 6 -C 12 aryl groups, which can be substituted by 1-3 halogen atoms, di-(C 1 -C 4 )-alkylamines and tri-(C 1 -C 4 ) alkylammonium.
• R 9a-e substituted and unsubstituted radicals with 4 to 8 carbon atoms are suitable.
• aryl radical R 6 , R 9a-e , R 10 , R 11a ,b, R 12 , R 13 , R 14 R 15a ,b substituted and unsubstituted carbocyclic or heterocyclic radicals, such as, e.g., phenyl, naphthyl, furyl, thienyl, pyridyl, pyrazolyl, pyrimidinyl, oxazolyl, pyridazinyl, pyrazinyl, quinolyl, which can be substituted several times by the groups that are defined in X, are suitable.
• alkoxy, acyl and acyloxy groups that are contained in R 2 , R 3 and X of general formula I are to contain 1 to 10 carbon atoms in each case, whereby methoxy, ethoxy, propoxy, isopropoxy, t-butyloxy, formyl, acetyl, propionyl and isopropionyl groups are preferred.
• the C 7 -C 16 aralkyl groups in R 6 , R 9a-e , R 11a ,b, R 12 , R 13 , R 14 , R 15a ,b can contain up to 14 C atoms, preferably 6 to 10 C atoms, in the ring and 1 to 4 atoms, preferably 1 to 2 atoms, in the alkyl chain.
• Preferred aralkyl radicals are, e.g., benzyl, phenylethyl, naphthylmethyl or naphthylethyl.
• the rings can be substituted several times by the groups that are defined in X.
• Free hydroxy groups in R 1 , R 2 , R 3 , R 4 , R 5 , R 10 and X can be modified functionally, for example by etherification or esterification, whereby free hydroxy groups are preferred.
• ether and acyl radicals the radicals that are known to one skilled in the art are suitable.
• Preferred are easily cleavable ether radicals, such as, for example, the tetrahydropyranyl, tetrahydrofuranyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tribenzylsilyl radical.
• acyl radicals e.g., acetyl, propionyl, butyryl, and benzoyl are suitable.
• Halogen in the definitions of X means fluorine, chlorine, bromine and iodine.
• inorganic and organic bases are suitable, as they are known to one skilled in the art for the formation of physiologically compatible salts.
• alkali hydroxides such as sodium or potassium hydroxide
• alkaline-earth hydroxides such as calcium hydroxide
• ammonia amines, such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, tris-(hydroxymethyl)-methylamine, etc.
• the invention also relates to a process for the production of borneol derivatives of formula I, which is characterized in that an olefin of general formula II ##STR4## in which R 4 , R 5 , X 1 and X 2 have the above-mentioned meanings and are optionally protected in hydroxyl groups that are contained in X 1 or X 2 , is epoxidated, and the epoxide formed is rearranged without isolation into an alcohol of general formula III ##STR5## in which R 4 , R 5 , X 1 and X 2 have the above-mentioned meanings and hydroxyl groups that are contained in R 1 , X 1 or X 2 are optionally protected, and this rearranged product is converted into a derivative of general formula I.
• an olefin of general formula II ##STR4## in which R 4 , R 5 , X 1 and X 2 have the above-mentioned meanings and are optionally protected in hydroxyl groups that are contained in
• reaction conditions of the above-named process stages are:
• the epoxidation of the double bond is carried out with a peroxy compound, such as, e.g., meta-chloroperbenzoic acid, peroxotrifluoroacetic acid, hydrogen peroxide, tert-butyl hydroperoxide optionally with the addition of a Lewis acid, such as, e.g., titanium tetraisopropoxide in an inert solvent, such as, e.g., dichloromethane, toluene at -40° C. to +40° C.
• a Lewis acid such as, e.g., titanium tetraisopropoxide in an inert solvent, such as, e.g., dichloromethane, toluene at -40° C. to +40° C.
• the reaction with tert-butyl hydroperoxide and titanium tetraisopropoxide in toluene at -10° C. to +25° C. is preferred.
• the rearrangement of the epoxide formed is catalyzed by acids, such as, e.g., para-toluenesulfonic acid, silica gel, acid ion exchanger resins and hydrochloric acid.
• acids such as, e.g., para-toluenesulfonic acid, silica gel, acid ion exchanger resins and hydrochloric acid.
• silica gel is preferred.
• 1,4-diazabicyclo[2.2.2]octane is deprotonated with a base, such as, e.g., metal hydrides (e.g., sodium hydride), alkali alcoholates (e.g., sodium methanolate, potassium-tert-butanolate), alkali hexamethyl disilazane (e.g., sodium hexamethyl disilazane), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), triethylamine, 4-(dimethylamino)pyridine (DMAP), and reacted with suitable carboxylic acid derivatives, such as, e.g., acid amides, acid halides, acid anhydrides in an inert solvent, such as, e.g., dichlorome
• suitable carboxylic acid derivatives such as, e.g., acid
• the functionalization of the olefinic double bond can be carried out according to the methods that are known to one skilled in the art.
• hydrogen can be stored, e.g., by catalyzed hydrogenation; hydroxyl groups can be introduced by water addition (hydroboration, oxymercurization) or by 1,2-bis-hydroxylation, e.g., with osmium tetroxide or potassium permanganate.
• the introduction of a carbonyl group (R 4 , R 5 together represent an oxygen atom) is possible after cleavage of the double bond, e.g., by ozonolysis or by oxidative cleavage of a 1,2-diol.
• a carbonyl group that is produced in such a way can be used, for example, reduced, alkylated or as a carbonyl component in a Wittig reaction in building modified ⁇ CHR 10 groups.
• the epoxide can be reacted by nucleophiles, such as, for example, water, carboxylic acid derivatives (carboxylic acids, carboxylic acid halides, carboxylic anhydrides), sulfonic acid derivatives (sulfonic acids, sulfonic acid halides, sulfonic anhydrides), amines, in the presence of mineral or organic acids, such as, for example, hydrochloric acid, para-toluenesulfonic acid or Lewis acids, such as, for example, boron trifluoride etherate, titanium tetraisopropoxide, cerium ammonium nitrate either in inert solvents or as solvents that act as nucleophiles at -70° C. up to +50° C.
• nucleophiles such as, for example, water, carboxylic acid derivatives (carboxylic acids, carboxylic acid halides, carboxylic anhydrides), sulfonic acid derivatives (sulf
• the new compounds of formula I are valuable pharmaceutical agents. They interact with tubulin by stabilizing the microtubuli formed and are thus able to influence cell division in a phase-specific manner. This relates mainly to quick-growing, neoplastic cells, whose growth is largely unaffected by intercellular regulating mechanisms. Active ingredients of this type are mainly suitable for treating diseases in which the influence of cell division can be therapeutically indicated as is the case, e.g., in the treatment of Alzheimer's disease, malaria, treatment of diseases that are caused by gram-negative bacteria, as well as for treating malignant tumors.
• malignant tumors for example, the treatment of ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia can be mentioned.
• the compounds according to the invention can be used by themselves or to achieve additive or synergistic actions in combination with other principles and classes of substances that can be used in tumor therapy.
• Platinum complexes such as, e.g., cis-platinum, carboplatinum,
• intercalating substances e.g., from the class of anthracyclins, such as, e.g., doxorubicin or from the class of anthrapyrazoles, such as, e.g., CI-941,
• tubulin substances that interact with tubulin, e.g., from the class of vinca alkaloids, such as, e.g., vincristine, vinblastine or from the class of taxanes, such as, e.g., taxol, taxotere or from the class of macrolides, such as, e.g., rhizoxin or other compounds, such as, e.g., colchicine, combretastatin A-4,
• DNA topoisomerase inhibitors such as, e.g., camptothecin, etoposide, topotecan, teniposide,
• folate- or pyrimidine-antimetabolites such as, e.g., lometrexol, gemcitubin,
• inhibitors of growth factors e.g., of PDGF, EGF, TGF ⁇ , EGF
• growth factors e.g., of PDGF, EGF, TGF ⁇ , EGF
• somatostatin e.g., somatostatin, suramin, bombesin antagonists
• inhibitors of protein tyrosine kinase or protein kinases A or C such as, e.g., erbstatin, genisteine, staurosporine, ilmofosine, 8-Cl-cAMP,
• antihormones from the class of antigestagens such as, e.g., mifepristone, onapristone, or from the class of antiestrogens, such as, e.g., tamoxifen, or from the class of antiandrogens, such as, e.g., cyproterone acetate,
• eicosanoids such as, e.g., PGl , PGE 1 , 6-oxo-PGE 1 as well as their more stable derivatives (e.g., iloprost, cicaprost, beraprost),
• inhibitors of the transmembrane Ca 2+ influx such as, e.g., verapamil, galopamil, flunarizine, diltiazem, nifedipine, nimodipine,
• neuroleptic agents such as, e.g., chlorpromazine, trifluoperazine, thioridazine, perphenazine,
• local anesthetics such as, e.g., carbanilat-Ca7, cinchocaine, carbanilat-Ca3, articaine, carbanilat, lidocaine,
• substances that inhibit angiogenesis such as, e.g., anti-VEGF-antibodies, endostatin B, interferon ⁇ , AGM 1470,
• the invention also relates to pharmaceutical agents that are based on pharmaceutically compatible compounds, i.e., compounds that are not toxic in the doses used, of general formula I, optionally together with the adjuvants and vehicles that are commonly used.
• the compounds according to the invention can be worked into pharmaceutical preparations for enteral, percutaneous, parenteral or local administration according to methods of galenicals that are known in the art. They can be administered in the form of tablets, coated tablets, gel capsules, granulates, suppositories, implants, injectable sterile aqueous or oily solutions, suspensions or emulsions, ointments, creams and gels.
• the active ingredient or active ingredients can be mixed with the adjuvants that are commonly used in galenicals, such as, e.g., gum arabic, talc, starch, mannitol, methyl cellulose, lactose, surfactants such as Tweens or Myrj, magnesium stearate, aqueous or non-aqueous vehicles, paraffin derivatives, wetting agents, dispersing agents, emulsifiers, preservatives and flavoring substances for taste correction (e.g., ethereal oils).
• the adjuvants that are commonly used in galenicals, such as, e.g., gum arabic, talc, starch, mannitol, methyl cellulose, lactose, surfactants such as Tweens or Myrj, magnesium stearate, aqueous or non-aqueous vehicles, paraffin derivatives, wetting agents, dispersing agents, emulsifiers, preservatives and flavoring substances for taste correction
• the invention thus also relates to pharmaceutical compositions, which as active ingredient contain at least one compound according to the invention.
• a dosage unit contains about 0.1-100 mg of active ingredient(s).
• the dosage e compounds according to the invention is approximately 0.1-1000 mg per day.
• Example 1a 26 mg (37 ⁇ mol) of nonpolar compound B that is presented according to Example 1a is reacted analogously to Example 1. After working-up and purification, 14 mg (25 ⁇ mol, 69%) of the title compound is obtained as a colorless oil.
• Example 3a 100 mg (142 ⁇ mol) of polar compound A that is presented according to Example 3a is reacted analogously to Example 1, and, after working-up and purification, 66 mg (120 ⁇ mol,85%) of the title compound is isolated as a colorless oil.
• Example 1b 80 mg (283 ⁇ mol) of the mixture that is presented according to Example 1b as well as 181 mg of the ⁇ -lactam that is presented according to Example 1d are reacted analogously to Example 1a, and, after working-up and purification, 24 mg (34 ⁇ mol, 12%) of title compound B as a nonpolar component as well as 100 mg (142 ⁇ mol, 50%) of title compound A as polar component are isolated respectively as a colorless oil.
• Example 3a 24 mg (34 ⁇ mol) of nonpolar compound B that is presented according to Example 3a is reacted analogously to Example 1, and, after working-up and purification, 10 mg (18 ⁇ mol, 54%) of the title compound is isolated as a colorless oil.
• Example 5a 22 mg (30 ⁇ mol) of the compound that is presented according to Example 5a is reacted analogously to Example 1, and, after working-up and purification, 9 mg (16 ⁇ mol, 52%) of the title compound is isolated as a colorless foam.
• Example 6a 15.6 mg (21 ⁇ mol) of the compound that is presented according to Example 6a is reacted analogously to Example 1, and, after working-up and purification, 8.6 mg (15 ⁇ mol, 71%) of the title compound is isolated as a colorless oil.
• Example 7a 16 mg (21 ⁇ mol) of the compound that is presented according to Example 7a is reacted analogously to Example 1, and, after working-up and purification, 7.8 mg (13 ⁇ mol, 63%) of the title compound is isolated as a colorless oil.
• Example 8a 6.5 mg (9.0 ⁇ mol) of the compound that is presented according to Example 8a is reacted analogously to Example 1 and after working-up and purification, 3.5 mg (6.2 ⁇ mol, 69%) of the title compound is isolated as a colorless oil.
• Example 9a 6.0 mg (8.3 ⁇ mol) of the compound that is presented according to Example 9a is reacted analogously to Example 1, and, after working-up and purification, 3.0 (5.3 ⁇ mol, 64%) of the title compound is isolated as a colorless oil.
• Example 10a 38 mg (53 ⁇ mol) of the compound that is presented according to Example 10a is reacted analogously to Example 1, and, after working-up and purification, 24 mg (43 ⁇ mol, 81%) of the title compound is isolated as a colorless oil.
• Example 1b 5.6 mg (20 ⁇ mol) of compound A that is presented according to Example 1b and is obtained enantiomer-free by crystallization as well as 22 mg of the ⁇ -lactam that is presented according to Example 1f are reacted analogously to Example 1a, and, after working-up, 28 mg of the title compound is isolated as crude product, which is further reacted without purification.
• Example 12a 11 mg (17 ⁇ mol) of the compound that is presented according to Example 12a is reacted analogously to Example 1a. After working-up and purification, 3.0 mg (6.0 ⁇ mol, 35%) of the title compound is isolated as a colorless oil.
• Example 13a 7.0 mg (10 ⁇ mol) of the compound that is presented according to Example 13a is reacted analogously to Example 1a. After working-up and purification, 2.0 mg (3.9 ⁇ mol, 39%) of the title compound is isolated as a colorless oil.
• Example 1b 10 mg (35 ⁇ mol) of compound A that is presented according to Example 1b as well as 21 mg of the ⁇ -lactam that is presented according to Example 1h are reacted analogously to Example 1a, and, after working-up and purification, 7 mg (10 ⁇ mol, 30%) of the title compound is isolated as a colorless oil.
• Example 14a 12 mg (17 ⁇ mol) of the compound that is presented according to Example 14a is reacted analogously to Example 1a. After working-up and purification, 4.0 mg (7.6 ⁇ mol, 44%) of the title compound is isolated as a colorless oil.
• Example 15a 12 mg (17 ⁇ mol) of the compound that is presented according to Example 15a is reacted analogously to Example 1a. After working-up and purification, 6.0 mg (11 ⁇ mol, 67%) of the title compound is obtained as a colorless oil.
• Example 16a 19 mg (26 ⁇ mol) of the compound that is presented according to Example 16a is reacted analogously to Example 1a. After working-up and purification, 9 mg (16 ⁇ mol, 60%) of the title compound is isolated as a colorless oil.
• Example 17a 25 mg (35 ⁇ mol) of the compound that is presented according to Example 17a is reacted analogously to Example 1a. After working-up and purification, 3.0 mg (5.5 ⁇ mol, 16%) of the title compound is isolated as a colorless oil.
• Example 18a 5.5 mg (7.5 ⁇ mol) of the compound that is presented according to Example 18a is reacted analogously to Example 1a. After working-up and purification, 4.0 mg (6.9 ⁇ mol, 92%) of the title compound is isolated as a colorless oil.
• Example 19a 11 mg (16 ⁇ mol) of the compound that is presented according to Example 19a is reacted analogously to Example 1a. After working-up and purification, 8.0 mg (14.6 ⁇ mol, 89%) of the title compound is isolated as a colorless oil.
• Example 20a 9.0 mg (12 ⁇ mol) of the diastereomer mixture that is presented according to Example 20a is reacted analogously to Example 1a. After working-up and purification, 2.3 mg (4 ⁇ mol, 34%) of title compound A is isolated as a more polar component as well as 1.1 mg (2 ⁇ mol, 16%) of title compound B as a more nonpolar component in each case as a colorless oil.
• Example 21a 9 mg (9.1 ⁇ mol) of the compound that is presented according to Example 21a is reacted analogously to Example 1a. After working-up and purification, 2 mg (2.9 ⁇ mol, 32%) of the title compound is isolated as a colorless oil.
• Example 1b 28 mg (100 ⁇ mol) of compound A that is presented according to Example 1b as well as 78 mg (2 equivalents) of the ⁇ -lactam that is presented according to Example 1h are reacted analogously to Example 1a, and, after working-up and purification, 9.0 mg (9.1 ⁇ mol, 9%) of the title compound is isolated as a colorless oil, as well as 53 mg of the compound that is described in Example 11a.
• Example 22a 25 mg (26 ⁇ mol) of the compound that is presented according to Example 22a is reacted analogously to Example 1a. After working-up and purification, 11 mg (17 ⁇ mol, 65%) of the title compound is isolated as a colorless oil.
• Example 1b 40 mg (142 ⁇ mol) of compound A that is presented according to Example 1b as well as 152 mg (3 equivalents) of the ⁇ -lactam that is presented according to Example 1f are reacted analogously to Example 1a, and, after working-up and purification, 25 mg (26 ⁇ mol, 18%) of the title compound is isolated as a colorless oil.
• Example 23a 2.8 mg (4.2 ⁇ mol) of compound A that is presented according to Example 23a is reacted analogously to Example 1a. After working-up and purification, 2.0 mg (4.0 ⁇ mol, 94%) of the title compound is isolated as a colorless oil.
• Example 1b 10 mg (35 ⁇ mol) of a mixture of compounds A and B that are presented according to Example 1b as well as 20 mg of the ⁇ -lactam that is presented according to Example 1p are reacted analogously to Example 1a, and, after working-up and purification, 2.8 mg (4.2 ⁇ mol, 12%) of title compound A as well as 2.3 mg (3.5 ⁇ mol; 10%) of title compound B are isolated in each case as a colorless oil.
• Example 24a 16 mg (23.7 ⁇ mol) of the compound that is presented according to Example 24a is reacted analogously to Example 1a. After working-up and purification, 7 mg (13.5 ⁇ mol, 57%) of the title compound is isolated as a colorless oil.
• Example 1b 50 mg (177 ⁇ mol) of compound A that is presented according to Example 1b as well as 114 mg of the ⁇ -lactam that is presented according to Example 1r are reacted analogously to Example 1a, and, after working-up and purification, 119 mg (176 ⁇ mol, 100%) of the title compound is isolated as a colorless oil.
• Example 25a 9 mg (13 ⁇ mol) of the compound that is presented according to Example 25a is reacted analogously to Example 1a. After working-up and purification, 5 mg (9 ⁇ mol, 70%) of the title compound is isolated as a colorless oil.
• Example 1b 5 mg (18 ⁇ mol) of compound A that is presented according to Example 1b as well as 12 mg of the ⁇ -lactam that is presented according to Example 1t are reacted analogously to Example 1a, and, after working-up and purification, 9.5 mg (13.5 ⁇ mol, 75%) of the title compound is isolated as a colorless oil.
• Example 26a 7 mg (10 ⁇ mol) of the compound that is presented according to Example 26a is reacted analogously to Example 1a. After working-up and purification, 4.8 mg (9.2 ⁇ mol, 90%) of the title compound is isolated as a colorless oil.
• Example 27a 8 mg (10.6 ⁇ mol) of the compound that is presented according to Example 27a is reacted analogously to Example 1a. After working-up and purification, 4 mg (6.7 ⁇ mol, 63%) of the title compound is isolated as a colorless oil.
• Example 26b 15 mg (25 ⁇ mol) of the compound that is presented according to Example 26b is reacted analogously to Example 26a. After working-up and purification, 6 mg (7.9 ⁇ mol, 32%) of the title compound is isolated as a colorless oil.
• Example 28a 16 mg (24 ⁇ mol) of the compound that is presented according to Example 28a is reacted analogously to Example 1a. After working-up and purification, 7 mg (13.5 ⁇ mol, 56%) of the title compound is isolated as a colorless oil.
• Example 29a 10 mg (15 ⁇ mol) of the compound that is presented according to Example 29a is reacted analogously to Example 1a. After working-up and purification, 4 mg (7.5 ⁇ mol, 50%) of the title compound is isolated as a colorless oil.
• Example 26b 20 mg (33 ⁇ mol) of the amine that is presented according to Example 26b is reacted analogously to Example 28a. After working-up and purification, 10 mg (14.5 ⁇ mol, 44%) of the title compound is isolated as a colorless oil.
• Example 23a 2.3 mg (3.5 ⁇ mol) of compound B that is presented according to Example 23a is reacted analogously to Example 1a. After working-up and purification, 1.6 mg (3.2 ⁇ mol, 91%) of the title compound is isolated as a colorless oil.
• Example 1b 30 mg (106 ⁇ mol) of the compound that is presented according to Example 1b as well as 49 mg of the ⁇ -lactam that is presented according to Example 1q are reacted analogously to Example 1a, and, after working-up and purification, 24 mg (41 ⁇ mol, 38%) of the title compounds is obtained as a colorless oil.
• Example 32a 22 mg (36 ⁇ mol) of the mixture that is presented according to Example 32a is reacted analogously to Example 1a. After working-up and purification, 2.5 mg (4.3 ⁇ mol, 12%) of title compound A as well as 3 mg (5.2 ⁇ mol, 14%) of title compound B are isolated in each case as a colorless oil.
• Example 1b 20 mg (71 ⁇ mol) of the compound that is presented according to Example 1b as well as 34 mg of the ⁇ -lactam that is presented according to Example 1s are reacted analogously to Example 1a, and, after working-up and purification, 22 mg (36 ⁇ mol, 51%) of the title compounds is isolated as a colorless oil.
• Example 33a 16 mg (24 ⁇ mol) of the mixture that is presented according to Example 33a is reacted analogously to Example 1a. After working-up and purification, 3 mg (6 ⁇ mol, 25%) of title compound A as well as 3 mg (6 ⁇ mol, 25%) of title compound B are isolated in each case as a colorless oil.
• Example 23a 26 mg (39 ⁇ mol) of the mixture that is presented according to Example 23a is reacted analogously to Example 19a. After working-up and purification, 16 mg (24 ⁇ mol, 62%) of the title compounds is isolated as a colorless oil.
• Example 34a 2 mg (3 ⁇ mol) of compound A that is presented according to Example 34a is reacted analogously to Example 1a. After working-up and purification, 1.3 mg (2.5 ⁇ mol, 85%) of the title compound is isolated as a colorless oil.
• Example 24a 102 mg (151 ⁇ mol) of the compound that is presented according to Example 24a is reacted analogously to Example 19a. After working-up and purification, 2 mg (3 ⁇ mol, 2%) of title compound A as well as 38 mg (56 ⁇ mol, 37%) of title compound B are isolated in each case as a colorless oil.
• Example 35a 38 mg (56 ⁇ mol) of compound B that is presented according to Example 35a is reacted analogously to Example 1a. After working-up and purification, 26 mg (50 ⁇ mol, 89%) of the title compound is isolated as a colorless oil.
• Example 36a 7 mg (10 ⁇ mol) of the compound that is presented according to Example 36a is reacted analogously to Example 1a. After working-up and purification, 5 mg (9 ⁇ mol, 90%) of the title compound is isolated as a colorless oil.
• Example 25a 20 mg (28 ⁇ mol) of the compound that is presented according to Example 25a is reacted analogously to Example 19a. After working-up and purification, 7 mg (10 ⁇ mol, 36%) of the title compound is isolated as a colorless oil.
• Example 37a 24 mg (36 ⁇ mol) of the compound that is presented according to Example 37a is reacted analogously to Example 1a. After working-up and purification, 13 mg (25 ⁇ mol, 70%) of the title compound is isolated as a colorless oil.
• Example 13a 60 mg (89 ⁇ mol) of the compound that is presented according to Example 13a is reacted analogously to Example 19a. After working-up and purification, 24 mg (36 ⁇ mol, 40%) of the title compound is isolated as a colorless oil.
• Example 38a 10 mg (14 ⁇ mol) of the mixture that is presented according to Example 38a is reacted analogously to Example 1a. After working-up and purification, 2 mg (3.5 ⁇ mol, 25%) of title compound A as well as 2.4 mg (4.2 ⁇ mol, 30%) of title compound B are isolated in each case as a colorless oil.
• Example 20a 18 mg (25 ⁇ mol) of the mixture that is presented according to Example 20a is reacted analogously to Example 19a. After working-up and purification, 10 mg (14 ⁇ mol, 56%) of the title compounds is isolated as a colorless oil.
• Example 39a 4 mg (6 ⁇ mol) of the compound that is presented according to Example 39a is reacted analogously to Example 1a. After working-up and purification, 2 mg (3.8 ⁇ mol, 63%) of the title compound is isolated as a colorless oil.
• Example 29a 10 mg (15 ⁇ mol) of the compound that is presented according to Example 29a is reacted analogously to Example 19a. After working-up and purification, 4 mg (6 ⁇ mol, 40%) of the title compound is isolated as a colorless oil.
• Example 40a 9 mg (13 ⁇ mol) of the compound that is presented according to Example 40a is reacted analogously to Example 1a. After working-up and purification, 5.6 mg (10.6 ⁇ mol, 81%) of the title compound is isolated as a colorless oil.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Steroid Compounds (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7755209

Family Applications (1)

Country Status (10)

Cited By (5)

Families Citing this family (1)

Citations (2)

• 1995
  • 1995-02-17 DE DE19506885A patent/DE19506885A1/de not_active Withdrawn
• 1996
  • 1996-02-19 US US08/894,180 patent/US6025507A/en not_active Expired - Fee Related
  • 1996-02-19 DE DE59607683T patent/DE59607683D1/de not_active Expired - Lifetime
  • 1996-02-19 WO PCT/DE1996/000297 patent/WO1996025392A1/de active IP Right Grant
  • 1996-02-19 PT PT96903893T patent/PT809627E/pt unknown
  • 1996-02-19 ES ES96903893T patent/ES2163001T3/es not_active Expired - Lifetime
  • 1996-02-19 CA CA002213211A patent/CA2213211A1/en not_active Abandoned
  • 1996-02-19 JP JP8524589A patent/JPH11500112A/ja not_active Ceased
  • 1996-02-19 EP EP96903893A patent/EP0809627B1/de not_active Expired - Lifetime
  • 1996-02-19 AT AT96903893T patent/ATE205473T1/de not_active IP Right Cessation
  • 1996-02-19 DK DK96903893T patent/DK0809627T3/da active

Patent Citations (2)

Also Published As

Similar Documents

Legal Events